Literature DB >> 10355807

Sequential neuromotor examination in children with intrauterine cocaine/polydrug exposure.

H M Belcher1, B K Shapiro, M Leppert, A M Butz, S Sellers, E Arch, K Kolodner, M Pulsifer, M K Lears, W E Kaufmann.   

Abstract

Data are presented on 157 newborn infants followed sequentially in a randomized home-based nursing-intervention trial for drug-exposed infants with follow up at 3 (N=118), 6 (N=124), and 12 months (N=77). The objectives of this study were to describe the longitudinal neurodevelopmental status of a cohort of children with intrauterine exposure to illicit drugs during their gestation, characterize the evolution of early tone abnormalities in a polydrug-exposed cohort, and determine whether neuromotor outcome is associated with drug-exposure patterns. For analysis, infants were grouped based on maternal drug-use pattern and the presence of drug metabolites in the neonatal drug screen. The sequential neuromotor examination was used at each age to define the neuromotor status of six domains and define categorical classifications as either normal, suspect, or abnormal. Multiple patterns of neuromotor abnormalities were observed during the neonatal period; most resolved over time. Axial hypotonia was a prominent finding in the neonatal period; however, it was infrequent in abnormal examinations at 12 months. Increased lower-extremity tone was a less frequent finding during the neonatal period. Infants whose neonatal urine drug screen was positive for both cocaine and opiates, were more likely than infants with negative urine drug screens, cocaine only, or opiate only drug screen results to have abnormal neuromotor examinations; while positive maternal drug screens for concurrent cocaine and opiate use were associated with peripheral hypertonia. Persistence of increased leg-extensor tone was found in 67% of the abnormal examinations at 12 months. Acquisition of rolling and walking was delayed in the drug-exposed cohort.

Entities:  

Mesh:

Year:  1999        PMID: 10355807     DOI: 10.1017/s0012162299000511

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  7 in total

1.  Neurobehavioral and Developmental Traiectories Associated with Level of Prenatal Cocaine Exposure.

Authors:  Claudia A Chiriboga; Louise Kuhn; Gail A Wasserman
Journal:  J Neurol Psychol       Date:  2014-11

Review 2.  Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review.

Authors:  D A Frank; M Augustyn; W G Knight; T Pell; B Zuckerman
Journal:  JAMA       Date:  2001-03-28       Impact factor: 56.272

Review 3.  Home visits during pregnancy and after birth for women with an alcohol or drug problem.

Authors:  Catherine Turnbull; David A Osborn
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

4.  Prenatal cocaine exposures and dose-related cocaine effects on infant tone and behavior.

Authors:  Claudia A Chiriboga; Louise Kuhn; Gail A Wasserman
Journal:  Neurotoxicol Teratol       Date:  2006-12-08       Impact factor: 3.763

Review 5.  Pharmacologic interventions for pregnant women enrolled in alcohol treatment.

Authors:  Erica J Smith; Steve Lui; Mishka Terplan
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

6.  Pharmacological treatment of neonatal opiate withdrawal: between the devil and the deep blue sea.

Authors:  Anthony Liu; Tracey Björkman; Caroline Stewart; Ralph Nanan
Journal:  Int J Pediatr       Date:  2011-05-23

Review 7.  Prenatal Opioid Exposure: Neurodevelopmental Consequences and Future Research Priorities.

Authors:  Elisabeth Conradt; Tess Flannery; Judy L Aschner; Robert D Annett; Lisa A Croen; Cristiane S Duarte; Alexander M Friedman; Constance Guille; Monique M Hedderson; Julie A Hofheimer; Miranda R Jones; Christine Ladd-Acosta; Monica McGrath; Angela Moreland; Jenae M Neiderhiser; Ruby H N Nguyen; Jonathan Posner; Judith L Ross; David A Savitz; Steven J Ondersma; Barry M Lester
Journal:  Pediatrics       Date:  2019-09       Impact factor: 9.703

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.